)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Herantis Pharma
Herantis Pharma (HRNTS) investor relations material
Herantis Pharma Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Result summary8 Jan, 2026
Study background and objectives
HER-096 is a small peptide designed to halt Parkinson's progression by mimicking CDNF and protecting dopamine neurons.
The study included 24 Parkinson's patients, with placebo and two HER-096 dose groups, receiving treatment twice weekly for four weeks.
Phase 1b focused on demonstrating biological response and target pathway engagement in humans.
Over 2.5 million biomarker data points were analyzed to assess biological effects through exploratory assessments.
Biomarker data are intended to de-risk and inform Phase 2 efficacy trials.
Key findings and data interpretation
HER-096 induced broad, dose-dependent proteomic changes in plasma, especially at 300 mg.
Biomarker shifts were observed in proteostasis, mitochondrial function, and neuroinflammation, consistent with the expected mechanism of action.
Targeted assays showed improved glutathione redox balance and reduced mitochondrial DNA lesions, indicating enhanced oxidative stress defense and mitochondrial benefit.
Concordant changes were observed in cerebrospinal fluid and nervous system-derived extracellular vesicles, supporting central and systemic effects.
Consistent, multi-layered data analysis increased confidence in the observed biological shifts and supports the disease-modifying potential of HER-096.
Implications for clinical development
Biomarker data provide proof of biology, bridging preclinical and clinical findings.
Results support dose selection (notably 300 mg) and inform exposure-response relationships and clinical endpoints for Phase 2.
Findings are expected to facilitate partnering and investor discussions for Phase 2 resourcing.
Mitochondrial markers and proteostasis changes are particularly relevant to Parkinson's pathology.
The data are seen as a major milestone, significantly reducing risk for further clinical development.
How will biomarker data guide Phase 2 dose selection?
How does data de-risk for partners?
Which biomarkers are prioritized for future trials?
Phase II dose selection rationale
How biomarker data strengthens partnering position
Translational significance of mitochondrial findings
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Herantis Pharma earnings date
H2 20255 Mar, 2026
Herantis Pharma
Next Herantis Pharma earnings date
H2 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Herantis Pharma Oyj is a Finnish biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. The company's lead program centers around HER-096, a small synthetic chemical designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF). This treatment aims to address the progression of Parkinson's by protecting neurons and enhancing their function. The company is headquartered in Espoo, Finland, and its shares are listed on the Helsinki Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage